What are the benefits of the CELLSEARCH® Circulating Tumor Cell Test?

As an adjunct to standard methods of monitoring, the CELLSEARCH® CTC Test provides:

  • An earlier assessment of prognosis than PSA in patients with metastatic prostate cancer*
  • Changes in disease status based on predictive prognosis at any time during the course of disease1-3
  • Added value when standard clinical indicators can be, and may remain, unclear1-3

Monitoring patients with metastatic cancer throughout the course of disease is critical to making informed clinical decisions. However, current methods for monitoring patients with metastatic breast, colorectal, and prostate* cancer are not without limitations, controversies, and uncertainties.1,4-7

Clinical studies have demonstrated that the number of circulating tumor cells correlates to disease prognosis and can provide an important marker for assessing patients’ status throughout the course of disease.1-3

The CELLSEARCH® CTC Test is the first and only clinically validated, FDA-cleared blood test for enumerating circulating tumor cells (CTCs) in patients with metastatic breast, colorectal, and prostate* cancer. The CELLSEARCH® CTC Test acts as a real-time liquid biopsy that predicts prognosis at any time during a patient's course of disease. Testing is easy – using the CellSave Preservative Tube, a blood sample is drawn at the point of care or at one of several laboratories that perform the test; CTCs are captured, analyzed and enumerated using the CELLSEARCH® System. View a list of laboratories that perform the CELLSEARCH® CTC Test to start testing patients.

Tracking your patients with serial CTC testing provides you with important, real-time prognostic information throughout the course of disease.

Review clinical studies and real case studies showing the role of CTC testing in patient treatment
Cristofanilli M, Hayes DF, Budd GT, et al. J Clin Oncol. 2005;23:1420-1430.
de Bono JS, Scher HI, Montgomery RB, et al. Clin Cancer Res. 2008;14:6302-6309.
Cohen SJ, Punt CJA, Iannotti N, et al. J Clin Oncol. 2008;26:3213-3221.
Henry NL, Hayes DF. Oncologist. 2006;11:541-552.
Monteil J, Mahmoudi N, Leobon S, et al. Anticancer Res. 2009;29:2563-2568.
Metser U, You J, McSweeney J, Freeman M, Hendler A. Am J Roentgenol. 2010;194:766-771.
Lee DK, Park JH, Kim JH, et al. Korean J Urol. 2010;51:358-361.